2007
DOI: 10.1038/sj.bjc.6603579
|View full text |Cite
|
Sign up to set email alerts
|

The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types

Abstract: In addition to new tumour antigens, new prognostic and diagnostic markers are needed for common cancers. In this study, we report the expression of Dickkopf-1 (DKK1) in multiple common cancers. This constitutes a comprehensive analysis of the DKK1 expression profile. Dickkopf-1 expression was evaluated by classical and quantitative reverse transcriptase -polymerase chain reaction (RT -PCR) and enzyme-linked immunosorbant assay for protein determination, in cancer lines and clinical specimens of several cancer … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

3
96
0
1

Year Published

2007
2007
2014
2014

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 142 publications
(104 citation statements)
references
References 27 publications
3
96
0
1
Order By: Relevance
“…21 This result was supported by our data in this study that DKK-1 was at low levels (18.69-239.52 pg/ml) in human vitreous, being strikingly lower than those in the plasma in controls. Our result suggests that DKK-1 may be produced at low levels in ocular tissues, and little of the circulating DKK-1 may leak into the ocular fluid under normal conditions.…”
Section: Discussionsupporting
confidence: 81%
“…21 This result was supported by our data in this study that DKK-1 was at low levels (18.69-239.52 pg/ml) in human vitreous, being strikingly lower than those in the plasma in controls. Our result suggests that DKK-1 may be produced at low levels in ocular tissues, and little of the circulating DKK-1 may leak into the ocular fluid under normal conditions.…”
Section: Discussionsupporting
confidence: 81%
“…Assays of Dkk-1 secretion could therefore represent a useful diagnostic and prognostic tool for the evaluation of OS patients. Dkk-1 is also upregulated by other malignant cell lines (Wirths et al, 2003;Forget et al, 2007), suggesting that serum Dkk-1 measurements may be useful for the evaluation of other types of malignancy, but the significance of Dkk-1 expression is not presently clear in tumours that do not affect bone. Although the data presented here demonstrate that Dkk-1 may contribute to OS pathogenesis by preventing repair of the surrounding osteoid as the tumour expands, Dkk-1 may act in an autocrine manner on the tumour cells too.…”
Section: Discussionmentioning
confidence: 99%
“…Furthermore, as mentioned above, aberrant Wnt/β-catenin signaling is involved in breast cancer development and progression. Indeed, Dkk1 is highly expressed in several breast cancer cell lines, including the MDA-MB-231 (osteolytic) and MCF-7 (osteolytic and osteoblastic) cell lines (Forget et al, 2007;Pinzone et al, 2009;Bu et al, 2008). Additionally, serum Dkk1 levels were elevated in patients with metastasized breast cancer in the bone compared to patients who were in complete remission (Voorzanger-Rousselot et al, 2007).…”
Section: Dkk1 In Breast Cancer Osteolytic Bone Metastasismentioning
confidence: 99%